GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » YoY EBITDA Growth

ARDX (Ardelyx) YoY EBITDA Growth : -48.94% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ardelyx's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -48.94%.

Ardelyx's EBITDA per Share for the three months ended in Mar. 2025 was $-0.14.

Ardelyx YoY EBITDA Growth Historical Data

The historical data trend for Ardelyx's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx YoY EBITDA Growth Chart

Ardelyx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.76 -49.59 73.48 34.38 71.83

Ardelyx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.67 29.85 -47.50 143.12 -48.94

Ardelyx YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Ardelyx's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.071--0.252)/ | -0.252 |
=71.83 %

Ardelyx's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(-0.14--0.094)/ | -0.094 |
=-48.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Ardelyx's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » YoY EBITDA Growth
Comparable Companies
DYN OCUL CLDX LQDA ADPT SPRY IOVA SNDX INVA AUPH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
41X:Germany 41X:Germany
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Website
https://www.ardelyx.com
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Executives
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010